Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH — Clinical Trial Site

54 Registered trials

24 Currently recruiting

Organisation

Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH

Location

Berlin, Germany

Identifier

ORG-100044105

Address

Lindenberger Weg 27, Buch, 13125, Germany

Departments

-
#173: Klinik für Pneumologie
#2005:Klinik fuer Pneumologie
2604:Klinik für Pneumologie
Clinic for Pneumology
Department of Pneumology
DEU005: Klinik für Pneumologie
Evangelische Lungenklinik
Evangelische Lungenklinik Berlin
Klinik fuer Pneumologie
Klinik für Pneumologie
Lunge
N/A
Oncology
Pneumologie
Pneumology
Pneumology and Cardiology
Studienabteilung
Studienzentrum

Clinical trials at this site (54)

Search interface

Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
Maintenance of durvalumab and olaparib after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive ext… Recruiting

2024-512373-27-00 Advanced/inoperable or metastatic small-cell lung cance 4 2024-09-30
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
Rezafungin for treatment of chronic pulmonary aspergillosis (CPA) in adults with limited treatment options Ended

2024-519575-26-00 Chronic pulmonary aspergillosis (CPA) 4 2025-07-25
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr… Ended

2024-511754-41-00 idiopathic pulmonary fibrosis 4 2025-05-29
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Non-Small Cell Lung Cancer 5 2025-02-21
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Unresectable Pleural Mesothelioma 5 2024-04-26
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either… Ended

2023-503357-35-00 Non-small Cell Lung Cancer (NSCLC) 4 2024-03-20
ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma Ended

2023-505054-17-00 metastatic TTF-1 negative lung adenocarcinoma 6 2023-09-15
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 4 2022-12-02
AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compare… Ended

2024-511625-55-00 EGFRmutated/T790M Mutation negative non-squamous NSCLC 6 2022-11-30
I-DXd in Patients With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Ended

2024-512368-79-00 Pretreated Extensive-stage Small Cell Lung Cancer (ES-S 4 2022-10-10
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended

2023-507933-12-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2022-08-18
A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce… Ended

2023-509943-28-00 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR 5 2022-05-18
A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-s… Ended

2023-503868-16-00 Small-Cell Lung Cancer (SCLC) 5 2022-02-14
A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (… Ended

2024-515902-15-00 Male and female adult patients with locally advanced or 4 2022-01-18
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200) Ended

2023-508214-42-00 Previously treated locally advanced and unresectable or 5 2020-05-25
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2 Ended

2023-505034-10-00 Locally Advanced or Metastatic Solid Tumors that Harbor 4 2016-08-01
A trial to learn how well osimertinib (AZD9291) works to prevent cancer from coming back after surgery and how safe it is compared to the pl… Ended

2023-506524-82-00 Stage IB-IIIA non-small cell lung carcinoma, with a cen 5 2015-10-21
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr… Ended

2023-506185-31-00 Idiopathic pulmonary fibrosis (IPF) 10 2024-07-18
A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patie… Ended

2022-502828-42-00 Idiopathic Pulmonary Fibrosis 4 2023-09-01